MetaCap

Anika Therapeutics (ANIK) vs K2 Capital Acquisition (KTWO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

K2 Capital Acquisition is the larger company by market cap ($203.0 million vs $177.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANIK+3.83%KTWO+2.53%
+76%+35%-7%
Feb 26, 20261 yearNov 19, 2026
ANIK-7.87%KTWO+2.64%
+55%+22%-11%
Feb 23, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANIK versus KTWO key metrics
MetricANIKKTWO
Share price$13.23$10.13
Market cap$177.22M$203.02M
1-day change-0.38%0.00%
YTD return+37.67%—
1-year return+33.91%—
5-year return-66.63%—
Forward P/E13.23—
EPS (TTM)$-0.03—
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$112.82M—
Revenue growth (YoY)-5.91%—
Net income (latest FY)$-10.88M—
Gross margin56.56%—
Operating margin-9.80%—
Net margin-9.64%—
52-week high$22.88$10.13
52-week low$9.01$0.00
Distance from 52-week high-42.18%0.00%
Analyst consensusstrong_buy—
Avg. price target upside+51.17%—
Average volume105.68K17.07K
Shares outstanding13.40M14.13M
Employees235—
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Anika Therapeutics

ANIK stock →

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.

Health Care · Medical/Dental Instruments · 235 employees

About K2 Capital Acquisition

KTWO stock →

K2 Capital Acquisition Corporation does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities in the physical AI or energy transition sectors.

Health Care · Medical/Dental Instruments

ANIK vs KTWO FAQ

Which is bigger, Anika Therapeutics or K2 Capital Acquisition?

K2 Capital Acquisition (KTWO) is larger, with a market capitalization of $203.02M compared with $177.22M for Anika Therapeutics (ANIK).

Are Anika Therapeutics and K2 Capital Acquisition in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons